Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Significant Decrease in Short Interest

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 62,900 shares, a decrease of 52.7% from the November 30th total of 132,900 shares. Based on an average trading volume of 211,300 shares, the short-interest ratio is currently 0.3 days. Currently, 1.2% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets reduced their target price on shares of Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating for the company in a research note on Monday, December 16th.

Alzamend Neuro Stock Down 3.2 %

ALZN traded down $0.04 during trading hours on Friday, hitting $1.20. The company’s stock had a trading volume of 117,759 shares, compared to its average volume of 477,311. Alzamend Neuro has a fifty-two week low of $1.06 and a fifty-two week high of $15.06. The company has a 50-day simple moving average of $1.38 and a 200 day simple moving average of $2.42.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.